CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Open accessThe DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.
Abstract
CTL-associated antigen 4 (CTLA4) blockade releases inhibitory controls on T cell activation and proliferation, inducing antitumor immunity in both preclinical and early clinical trials. We examined the mechanisms of action of anti-CTLA4 and a GM-CSF-transduced tumor cell vaccine (Gvax) and their impact on the balance of effector T cells (Teffs) and Tregs in an in vivo model of B16/BL6 melanoma. Tumor challenge increased the frequency of Tregs in lymph nodes, and untreated tumors became infiltrated by CD4+Foxp3- and CD4+Foxp3+ T cells but few CD8+ T cells. Anti-CTLA4 did not deplete Tregs or permanently impair their function but acted in a cell-intrinsic manner on both Tregs and Teffs, allowing them to expand, most likely in response to self antigen. While Gvax primed the tumor-reactive Teff compartment, inducing activation, tumor infiltration, and a delay in tumor growth, the combination with CTLA4 blockade induced greater infiltration and a striking change in the intratumor balance of Tregs and Teffs that directly correlated with tumor rejection. The data suggest that Tregs control both CD4+ and CD8+ T cell activity within the tumor, highlight the importance of the intratumor ratio of effectors to regulators, and demonstrate inversion of the ratio and correlation with tumor rejection during Gvax/anti-CTLA4 immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-CTLA-4 and anti-PD-1 antibodies have been successful in depleting tumor-infiltrating Tregs and increasing the effector T cell (Teff) to Treg ratio in the tumor microenvironment (Curran et al., 2010; Quezada et al., 2006; Simpson et al., 2013).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Quezada et al., 2006
Experimental — accuracy not yet measuredIn the citing paper
“Mouse melanoma models, for example, have shown that the combination of anti-CTLA-4 with cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or with agonistic antibodies targeting costimulatory receptors such as CD40, increased tumor rejection in a synergistic manner (121, 122).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [121]
In the citing paper
“In general, anti-CTLA4 expands CD4 effector T cells (Teff) with subsequent increase in the Teff/ Treg ratio in responding tumors (22).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Cited by
Items 401–500 of 697
Expression of CTLA‐4 and FOXP3 in cis protects from lethal lymphoproliferative disease
Chikuma, S., & Bluestone, J. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737159 · Cited by 33
Strategies to Overcome Obstacles to Successful Immunotherapy of Melanoma
Pandolfi, F., Cianci, R., Lolli, S., Dunn, I. S., Newton, E. E., Haggerty, T. J., Boyle, L. A., & Kurnick, J. T. (2008) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200802100302 · Cited by 32
Concepts for Immunotherapies in Gliomas
Platten, M., & Reardon, D. A. (2018) · Seminars in Neurology · doi:10.1055/s-0037-1620274 · Cited by 35
Vaccines based on abnormal self-antigens as tumor-associated antigens: Immune regulation
Farkas, A. M., & Finn, O. J. (2010) · Seminars in Immunology · doi:10.1016/j.smim.2010.03.003 · Cited by 32
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1
Mok, S., Liu, H., Çobanoğlu, D. A., Anang, N.-A. A. S., Mancuso, J. J., Wherry, E. J., & Allison, J. P. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2418985122 · Cited by 33
Melanoma: oncogenic drivers and the immune system.
Karachaliou, N., Pilotto, S., Teixidó, C., Viteri, S., González‐Cao, M., Riso, A. A., Morales-Espinosa, D., Molina‐Vila, M. Á., CHAIB-OUKADOUR, I., Santarpía, M., et al. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.06 · Cited by 34
Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).
Cameron, S., Gieselmann, M., Blaschke, M., Ramadori, G. P., & FÜZESI, L. (2014) · PubMed Central · Cited by 30
Interaction of molecular alterations with immune response in melanoma
Sloane, R. A. S., Gopalakrishnan, V., Reddy, S. M., Zhang, X., Reuben, A., & Wargo, J. A. (2017) · Cancer · doi:10.1002/cncr.30681 · Cited by 33
Modulation of CTLA-4 and GITR for Cancer Immunotherapy
Avogadri, F., Yuan, J. D., Yang, A. S., Schaer, D., & Wolchok, J. D. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_49 · Cited by 33
“For instance, blocking CTLA-4 on Tregs alone is not sufficient to promote T cell mediated tumor rejection in a mousemelanomamodel that is responsive to anti-CTLA-4 treatment in combination with vaccine (Peggs et al. 2009; Quezada et al. 2006).”
BackgroundPanfilis, G. D., Campanini, N., Santini, M., Mori, G., Tognetti, E., Maestri, R., Lombardi, M., Froio, E., Ferrari, D., & Ricci, R. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701046 · Cited by 30
“, 2006), as suggested not only in experimental murine melanoma (Shimizu et al., 1999; Steitz et al., 2001; Sutmuller et al., 2001, Nagai et al., 2004; Antony et al., 2005; Li et al., 2006; Quezada et al., 2006; Nair et al., 2007), but also in human melanoma patients (Chakraborty et al.”
BackgroundRoussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
“CTLA-4 is preferentially expressed on Ipilimumab induces durable responses, with some patients achieving survival beyond 10 years [56]. immunosuppressive Tregs [58].”
Tumour escape mechanisms and their therapeutic implications in combination tumour therapy
Bhutia, S. K., Mallick, S. K., & Maiti, T. K. (2010) · Cell Biology International · doi:10.1042/cbi20090206 · Cited by 33
Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines
Huang, S., Zhu, Y., Zhang, L., & Zhang, Z. (2022) · Advanced Materials · doi:10.1002/adma.202107946 · Cited by 29
Gerber, S. A., Sorensen, E. W., Sedlacek, A. L., Lim, J. Y. H., Skrombolas, D., Frelinger, J. G., & Lord, E. M. (2012) · Immunology · doi:10.1111/imm.12037 · Cited by 31
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy
Reardon, D. A., Gilbert, M. R., Wick, W., & Liau, L. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov178 · Cited by 30
Piconese, S., & Colombo, M. P. (2007) · Springer eBooks · doi:10.1007/978-0-387-69118-3_4 · Cited by 29
“The blockade of CTLA-4 does not result in Treg depletion, but in their expansion in lymph nodes (Quezada et al., 2006); nevertheless, in some instances, it inhibits their suppressive function.”
BackgroundXiao, H., Peng, Y., Yuan, H., Huang, L., Guo, Z. S., Bartlett, D. L., Fu, N., Munn, D. H., Mellor, A. L., & He, Y. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203470 · Cited by 27
“the Teff/Treg ratio correlated to antitumor effect (36, 37).”
BackgroundGeneration of colon cancer–derived tumor-infiltrating T cells (TILs) for adoptive cell therapy
Albrecht, H. C., Gustavus, D., Schwanemann, J., Dammermann, W., Lippek, F., Weylandt, K. H., Hoffmeister, H., & Gretschel, S. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.009 · Cited by 29
Liang, S. C., Москаленко, М., Roey, M. V., & Jooss, K. U. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.05.011 · Cited by 31
Le, D. T., Ladle, B. H., Lee, T. T., Weiss, V. L., Yao, X., Leubner, A., Armstrong, T. D., & Jaffee, E. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25693 · Cited by 28
“Other studies suggest that it is Teff/ Treg ratios that correlate with effective anti-tumor responses.(21,22) In Hodgkin’s lymphoma, Tregs in the tumor microenvironment are actually associated with improved clinical outcomes.”
BackgroundImmunotherapy for liver tumors: present status and future prospects
Matar, P., Alaniz, L. D., Rozados, V. R., Aquino, J. B., Malvicini, M., Atorrasagasti, C., Gidekel, M., Silva, M., Scharovsky, O. G., & Mazzolini, G. D. (2009) · Journal of Biomedical Science · doi:10.1186/1423-0127-16-30 · Cited by 32
Werneck, M. B. F., Vieira‐de‐Abreu, A., Chammas, R. J., & Viola, J. P. B. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0964-4 · Cited by 27
“Increased Treg numbers do not correlate with inhibition of anti-tumor responses [40], and FOXP3 might not be a good marker in this system since in the absence of NFAT1 its capacity for inducing suppression-associated genes may be impaired [36].”
BackgroundMandl, S. J., Rountree, R. B., Dalpozzo, K., Do, L., Lombardo, J. R., Schoonmaker, P. L., Dirmeier, U., Steigerwald, R., Giffon, T. D., Laus, R., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1077-4 · Cited by 27
“Anti-tumor activity was accompanied by a high density of activated CD8 T cells along with a clear reduction in the percentage of Treg cells in the lungs of animals treated with MVA-BN -HER2, thus resulting in a crucial shift in the balance of Teff to Treg cells in favor of effector T cells [22].”
BackgroundGritzapis, A. D., Voutsas, I. F., Lekka, E., Papamichail, M., & Baxevanis, C. N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2517 · Cited by 27
“It has recently been shown that an increased effector to Treg ratio in the tumor following CTLA4 blockade and GM-CSF combination immunotherapy correlates with improved survival of tumorbearing mice (23).”
BackgroundCaudana, P., Núñez, N. G., Rochère, P. D. L., Pinto, A., Denizeau, J., Alonso, R., Niborski, L. L., Lantz, O. J., Sedlik, C., & Piaggio, E. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0697 · Cited by 29
“Therapeutic efficacy of anticancer immunotherapies is associated with increased CD8/Treg ratios (22, 24).”
BackgroundHurst, J. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci84236 · Cited by 27
Methods for improving the immunogenicity and efficacy of cancer vaccines
Pilla, L., Ferrone, S., & Maccalli, C. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1485649 · Cited by 28
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Kato, T., Fukushima, H., Furusawa, A., Okada, R., Wakiyama, H., Furumoto, H., Okuyama, S., Takao, S., Choyke, P. L., & Kobayashi, H. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2152248 · Cited by 26
Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science
Shen, C., & Chen, Y.-S. (2015) · Biomedical Journal · doi:10.4103/2319-4170.151150 · Cited by 30
“[12,13] This subsequently led to development of a monoclonal antibody drug, which has undergone clinical trials against stage 4 melanoma and was approved for treatment of mela‐ noma by the US FDA in 2011.”
BackgroundAnti–CTL-Associated Antigen 4: Are Regulatory T Cells a Target?
Gabriel, E. M., & Lattime, E. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2820 · Cited by 27
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy
Mok, S., Çobanoğlu, D. A., Liu, H., Mancuso, J. J., & Allison, J. P. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2404661121 · Cited by 28
Xiang, S., Li, S., & Xu, J. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70345 · Cited by 36
“196 In another mouse model of tumour transplantation, ROR γ t agonists regulate the TME by promoting CD8 + T cell infiltration, thus enhancing anti-PD-1 therapy.”
New Immuno-oncology Targets and Resistance Mechanisms
Tokaz, M. C., Baik, C. S., Houghton, A. M., & Tseng, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01005-8 · Cited by 26
The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy
Kim, H. J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0153 · Cited by 29
Jenq, R. R., King, C. G., Volk, C., Suh, D. Y., Smith, O. M., Rao, U. K., Yim, N. L., Holland, A. M., Lu, S. X., Zakrzewski, J. L., et al. (2008) · Blood · doi:10.1182/blood-2008-05-155697 · Cited by 27
Progress in nanomedicine for sonodynamic immunotherapy of tumors
Feng, Z., Wang, Z., Xiang, X., Wang, L., Du, F., Xiao, X., Zhu, B., Rong, X., & Qiu, L. (2024) · EngMedicine · doi:10.1016/j.engmed.2024.100027 · Cited by 25
Triple-modality therapy maximizes antitumor immune responses in a mouse model of mesothelioma
Murakami, J., Wu, L., Kohno, M., Chan, M.-L., Zhao, Y. D., Yun, Z., Cho, J., & de Perrot, M. E. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd9882 · Cited by 25
“The increased Teff/Treg ratio within the tumors after dual immunotherapy (IL-15SA/DTA-1) may play an important role in enhancing the antitumor effect of LRT, as previous studies have found (34, 35).”
ResultAdvances in tumour immunotherapy
King, J. P., Waxman, J. H., & Stauss, H. J. (2008) · QJM · doi:10.1093/qjmed/hcn050 · Cited by 33
“In a murine melanoma model, CTLA-4 blockade in combination with granulocyte macrophage colony stimulating factor (GM-CSF) immunotherapy has been shown to cause tumour regression which correlated with a change in the balance of Tregs and effector T cells in the tumour microenvironment.(31) There are two fully human ant…”
BackgroundWhat does the future hold for immunotherapy in cancer?
Naidoo, J., Li, B. T., Schindler, K., & Page, D. B. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.05 · Cited by 22
“com ratio of effector T-cells to regulatory T-cells (21).”
BackgroundPotential of natural products and gut microbiome in tumor immunotherapy
Cao, L., Wang, X., Ma, X., Xu, M., & Li, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01032-7 · Cited by 25
Targeting Cytotoxic T-Lymphocyte Antigen 4 in Immunotherapies for Melanoma and Other Cancers
Page, D. B., Yuan, J. D., & Wolchok, J. D. (2010) · Immunotherapy · doi:10.2217/imt.10.21 · Cited by 23
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists
Callahan, M. K., & Wolchok, J. D. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.008 · Cited by 23
Clark, P. A., Sriramaneni, R. N., Bates, A. M., Jin, W. J., Jagodinsky, J. C., Hernandez, R. T., Le, T. Q. H., Jeffery, J. J., Marsh, I. R., Grudzinski, J. J., et al. (2021) · Radiation Research · doi:10.1667/rade-20-00237.1 · Cited by 23
RNA as performance-enhancers for dendritic cells
Boczkowski, D., & Nair, S. K. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003614749 · Cited by 22
“Blocking antibodies against CTLA-4 interfere with its binding to its ligands and ‘removes the brakes’ from the resulting T cell response, resulting in increased T cell proliferation and activation [77,79-81].”
BackgroundRole of gut microbiome on immunotherapy efficacy in melanoma
Bibbò, S., Ianiro, G., Giambò, F., Settanni, C. R., Cammarota, G., & Gasbarrini, A. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1926759 · Cited by 25
“Several evidences suggest that CTLA-4 blockade results in direct activation effector cells (CD4 + and CD8+), and anti-CTLA-4 monoclonal antibody therapy has considered a promising tool in a several type of cancers, particularly melanoma.(12)”
BackgroundBelgiovine, C., Mebelli, K., Raffaele, A., Cicco, M. D., Rotella, J., Pedrazzoli, P., Zecca, M., Riccipetitoni, G., & Comoli, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063225 · Cited by 25
“In pediatric tumors, the expression of CTLA-4 was detected in glioblastoma, neuroblastoma, and sarcomas, particularly in osteosarcoma, suggesting its potential role as a target for immunotherapy [92,95,102,109].”
BackgroundRegulatory T cells in the immunotherapy of melanoma
Ouyang, Z., Wu, H., Li, L., Luo, Y., Li, X., & Huang, G. (2015) · Tumor Biology · doi:10.1007/s13277-015-4315-0 · Cited by 25
“Ipilimumab was demonstrated to be effective in a phase III trial and received FDA approval for treating metastatic melanoma in 2011 [74].”
BackgroundDriessens, G., Gordower, L., Nuttin, L., Stordeur, P., Blocklet, D., Egrise, D., Velu, T. J., & Bruyns, C. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0500-y · Cited by 22
“In agreement with a recent paper from Allison’s group, the success of our vaccination strategy seems to partially depend on the change in the intratumor ratio of eVector (CD4+ but mostly CD8+ TIL) to regulator T cells [ 29 ].”
BackgroundAbbott, D. J., Blanchfield, L., Martinson, D. A., Russell, S. C., Taslim, N., Curtis, A. D., & Mannie, M. D. (2011) · BMC Immunology · doi:10.1186/1471-2172-12-72 · Cited by 23
Zaidi, N., Quezada, S. A., Kuroiwa, J. M. Y., Zhang, L., Jaffee, E. M., Steinman, R. M., & Wang, B. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14049 · Cited by 23
Gupta, S., Termini, J. M., Rivas, Y., Otero, M. A., Raffa, F. N., Bhat, V. S., Farooq, A., & Stone, G. W. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.081 · Cited by 23
“However, we observed slower tumor growth in mice treated with the “gold standard” GVAX vaccine, consistent with previous reports [27].”
MethodResultdos Santos, L. I., Galvão-Filho, B., de Faria, P. C., Junqueira, C., Dutra, M. S., Teixeira, S. M. R., Rodrigues, M. M., Ritter, G., Bannard, O., Fearon, D. T., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1634-8 · Cited by 23
“cal adjuvants or a tumor-specific vaccine [49].”
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska, M. E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00992-0 · Cited by 26
“Author contributions MRS conducted a comprehensive review and analysis of the available literature, wrote the manuscript and prepared figures. intratumoral ratio of Tregs to Teffs directly correlated with tumor rejection [161].”
Vogt, A., Sadeghlar, F., Ayub, T. H., Schneider, C., Möhring, C., Zhou, T., Mahn, R., Bartels, A., Praktiknjo, M., Kornek, M., et al. (2021) · Cancers · doi:10.3390/cancers13133375 · Cited by 21
Machiraju, D., Schäfer, S., & Hassel, J. C. (2021) · Life · doi:10.3390/life11121318 · Cited by 22
“Consequently, increased ratios of Tregs over CD8+ T cells within the TME is a significant factor that facilitates immune evasion and tumor growth [46,47].”
BackgroundAnti‐tumor effects of miR ‐34a by regulating immune cells in the tumor microenvironment
Yin, M., Zhang, Z., & Wang, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.5826 · Cited by 23
Mirmonsef, P., Tan, G. G. Y., Zhou, G., Morino, T., Noonan, K. A., Borrello, I., & Levitsky, H. I. (2007) · Blood · doi:10.1182/blood-2007-06-096586 · Cited by 21
Villarreal, D. O., Chin, D., Smith, M. A., Luistro, L. L., & Snyder, L. A. (2017) · Oncotarget · doi:10.18632/oncotarget.16605 · Cited by 21
“As a result, the CD8/Treg ratios within the tumor increased markedly, with the triple combination therapy being statistically superior to any other Ab combination therapy (Figure 4C), a response which has been described as a correlate for therapeutic efficacy in the melanoma model [33].”
Li, B., Simmons, A. D., Du, T., Lin, C. Y.-C., Москаленко, М., Gonzalez-Edick, M., VanRoey, M. J., & Jooss, K. U. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.07.008 · Cited by 20
Immune classification of colorectal cancer patients: impressive but how complete?
Baxevanis, C. N., Papamichail, M., & Perez, S. A. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.751971 · Cited by 24
“For instance, TGF-b, IL-10 and IL-17 have been demonstrated to initiate immunosuppressive networks whereas Th1-associated IFN-g stimulates tumor-specific immunity [10-16].”
BackgroundGhosh, S., Sarkar, M., Ghosh, T., Guha, I., Bhuniya, A., Biswas, J., Mallick, A., Bose, A., & Baral, R. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.05.004 · Cited by 21
Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors
Davar, D., & Zarour, H. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_2 · Cited by 22
Melanoma immunotherapy: strategies to overcome pharmacological resistance
Trojaniello, C., Vitale, M. G., Scarpato, L., Esposito, A., & Ascierto, P. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1745634 · Cited by 23
“tration and CD8/Treg ratio in these tumors [82].”
BackgroundInfluentialThe crosstalk between ferroptosis and autophagy in cancer
Lv, X., Wang, B., Dong, M., Wang, W., Tang, W., Qin, J., Gao, Y., & Wei, Y. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2289362 · Cited by 19
“…T-lymphocyte antigen 4 (CTLA-4) immunotherapy is related to the ratio of effector T cells to Tregs in the TME, and the mechanism has been used to potentiate the efficacy of CTLA-4 blockade by increasing the ratio of effector T cells and Tregs with GM-CSF-transduced tumor cell vaccine [75].”
BackgroundSantiago-Sánchez, G. S., Hodge, J. W., & Fabian, K. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993624 · Cited by 21
Cho, O., Lee, J.-W., Kim, H., Jeong, Y.-J., & Heo, T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121559 · Cited by 22
Intratumoral IL15 Improves Efficacy of Near-Infrared Photoimmunotherapy
Fukushima, H., Furusawa, A., Kato, T., Wakiyama, H., Takao, S., Okuyama, S., Choyke, P. L., & Kobayashi, H. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0210 · Cited by 19
Abenavoli, L., Montori, M., Svegliati‐Baroni, G., Argenziano, M. E., Giorgi, F., Scarlata, G. G. M., Ponziani, F. R., & Scarpellini, E. (2023) · Medicina · doi:10.3390/medicina59081427 · Cited by 23
“Moreover, an altered Firmicutes/Bacteroidetes ratio (<0.5 or >1.5) and a low Prevotella/Bacteroides ratio were significantly correlated with the non-responder profile.”
InfluentialWolf, B., Schwarzer, A., Côté, A. L., Hampton, T. H., Schwaab, T., Huarte, E., Tomlinson, C. R., Gui, J., Fisher, J. L., Fadul, C. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050221 · Cited by 19
“[38,39] Taken together with our data, these studies suggest that suppressing CTLA4 signaling may be necessary but not sufficient for robust clinical response in cancer patients.”
BackgroundEvaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis
Arriola, E., Wheater, M. J., Lopez, M. A., Thomas, G. J., & Ottensmeier, C. H. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1209615 · Cited by 21
Karakatsanis, S., Bertsias, G. K., Roussou, P. A., & Boumpas, D. T. (2013) · Hematological Oncology · doi:10.1002/hon.2098 · Cited by 21
Regulatory T cells as therapeutic target in Hodgkin's lymphoma
Koenecke, C., Ukena, S. N., Ganser, A., & Franzke, A. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.6.769 · Cited by 21
“Unfortunately, both molecules could lead to the expansion of the Treg cell populations with autoimmune phenomenons [144,145] .”
BackgroundTumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
McCarthy, P. M., Valdera, F. A., Smolinsky, T. R., Adams, A. M., O’Shea, A. E., Thomas, K. K., Decar, S. G. V., Carpenter, E. L., Tiwari, A., Myers, J. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1090533 · Cited by 17
Palmeri, J. R., Lax, B. M., Peters, J. M., Duhamel, L., Stinson, J. A., Santollani, L., Lutz, E. A., Pinney, W., Bryson, B. D., & Wittrup, K. D. (2024) · Nature Communications · doi:10.1038/s41467-024-45625-0 · Cited by 19
Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models
Persson, J., Beyer, I., Yumul, R., Li, Z.-Y., Kiem, H., Roffler, S. R., & Lieber, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022303 · Cited by 21
“Systemic administration of this antibody has been shown before to trigger tumor-destructive immune responses in several mouse tumor models [24,25].”
BackgroundMolecular analysis of melanoma-induced sentinel lymph node immune dysfunction
Lee, J. H., Chen, Y., Chan, J. L. ‐., Qian, Y., & Goydos, J. S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-0982-x · Cited by 19
“Using an animal model, Quezada et al. [ 28 ] have shown that GM-CSF-transduced tumor cell vaccine (Gvax) showed increase in CD4 + TeV/Treg ratio within the tumor,”
MethodFuture directions in tumor immunotherapy: CTLA4 blockade
Gulley, J. L., & Dahut, W. L. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0749 · Cited by 18
“A recent study showed that anti-CTLA4 monotherapy proportionally increased Tregs and effector T cells (Teffs) within the tumor, whereas CTLA4 blockade with vaccine increased Teffs more than Tregs and, unlike CTLA4 blockade alone, induced tumor rejection”
BackgroundTargeting protein kinases benefits cancer immunotherapy
Zhang, Z., Bu, L., Luo, J., & Guo, J. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188738 · Cited by 20
Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
Elkord, E., Hawkins, R. E., & Stern, P. L. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.385 · Cited by 17
“(2008) 8(4) 391 GM-CSF-transduced tumour cell vaccine (Gvax) altered the intratumour balance of Tregs and T effector cells and induced tumour rejection [97] .”
BackgroundWakiyama, H., Furusawa, A., Okada, R., Inagaki, F. F., Kato, T., Furumoto, H., Fukushima, H., Okuyama, S., Choyke, P. L., & Kobayashi, H. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03205-5 · Cited by 16
Schaer, D., Li, Y., Merghoub, T., Rizzuto, G. A., Shemesh, A. J., Cohen, A. D., Li, Y., Avogadri, F., Toledo‐Crow, R., Houghton, A. N., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021214 · Cited by 17
“Prior research, by our group and others, has been limited to examining tumor infiltrating lymphocytes during late stages of tumor growth (greater than 14 days after tumor challenge), or during immunotherapy [2,15].”
Regulatory T cells as therapeutic targets and mediators
Sharma, A., & Rudra, D. (2019) · International Reviews of Immunology · doi:10.1080/08830185.2019.1621310 · Cited by 18
“A high ratio of T effector cells to Tregs has been indicative of successful immunotherapy in both mice and humans [123,124].”
BackgroundAkhuba, L. G., Tigai, Z. G., & Shek, D. (2022) · Biomedicines · doi:10.3390/biomedicines10123196 · Cited by 19
“GVAX is a cell-based vaccine that transfers an allogeneic tumor cell, engineered to express granulocyte-macrophage colonystimulating factor (GM-CSF) [55].”
BackgroundStinson, J. A., Barbosa, M. M. P., Sheen, A. M., Momin, N., Fink, E., Hampel, J., Selting, K. A., Kamerer, R. L., Bailey, K. L., Wittrup, K. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0861 · Cited by 17
Gritzapis, A. D., Voutsas, I. F., & Baxevanis, C. N. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1113-4 · Cited by 14
“Tumor inWltrating lymphocytes (TIL) were isolated as described [26].”
BackgroundMethodUsing Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy
Gough, M. J., Sharon, S., Crittenden, M. R., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.002 · Cited by 16
Organized immune cell interactions within tumors sustain a productive T-cell response
Cardenas, M. A., Prokhnevska, N., & Kissick, H. T. (2020) · International Immunology · doi:10.1093/intimm/dxaa057 · Cited by 14
Turning up the heat: CTLA4 blockade in urothelial cancer
Stockem, C. F., Galsky, M. D., & van der Heijden, M. S. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00801-7 · Cited by 17
“In a melanoma mouse model, CD8 + T cell numbers within lymph nodes decreased upon CTLA4 blockade plus a GM-CSF-transduced tumour cell vaccine 69 .”
Using monoclonal antibodies to stimulate antitumor cellular immunity
Durrant, L. G., Pudney, V. A., & Spendlove, I. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.33 · Cited by 14
Martínez‐Forero, I., Okada, H., Topalian, S. L., Gajewski, T. F., Korman, A. J., & Melero, I. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-108 · Cited by 15
“The above strategy may be used to endow cellular vaccines with immune stimulating properties, through genetically introduced expression of molecules such as GM-CSF, Flt-3-ligand, ICOS-ligand and others [32,33].”
BackgroundManrique-Rincón, A., Ruas, L. P., Fogagnolo, C. T., Brenneman, R., Berezhnoy, A., Castelucci, B. G., Consonni, S. R., Gilboa, E., & Bajgelman, M. C. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.05.005 · Cited by 15
“Data in the literature also have shown other therapeutic approaches that explore enhancement of antitumor response combining checkpoint inhibitors such as anti-PD1 or anti-CTLA4 with Treg inhibition, which suggests the potential of this strategy.(52,53) The approach using sasRNA-aptamer has two levels of selectivity:…”
BackgroundResistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL
Hare, L., Burke, G. A. A., & Turner, S. D. (2021) · Cancers · doi:10.3390/cancers13236003 · Cited by 14
Weng, S., Matsuura, S., Mowery, C. T., Stoner, S. A., Lam, K., Ran, D., Davis, A. G., Lo, M.-C., & Zhang, D.-E. (2016) · Leukemia · doi:10.1038/leu.2016.167 · Cited by 14
Rausch, J., Lopez, P. A., Bialojan, A., Denny, M., Langguth, P., Probst, H. C., Schild, H., & Radsak, M. P. (2017) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2017.06.013 · Cited by 14
“It has been assumed that a higher antibody dosage increases the amount of Treg cells in the tumor environment, thus being therapy-limiting [23,24].”
BackgroundFu, Z., Zhang, D., Guo, Y., Han, S., Guo, F., Bai, J., Wan, Y.-N., Guan, G., Sun, K.-W., & Yang, N. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2492 · Cited by 14
“However, CD4+ forkhead box (Fox)p3+ Tregs contribute to the inhibition of autoimmunity and prevent excessive immune response to pathogens (33).”
BackgroundInfluence of human immune cells on cancer: studies at the University of Colorado
Bruno, T. C., French, J. D., Jordan, K. R., Ramirez, O., Sippel, T. R., Borges, V. F., Haugen, B. R., McCarter, M. D., Waziri, A. E., & Slansky, J. E. (2012) · Immunologic Research · doi:10.1007/s12026-012-8346-y · Cited by 15
“Although studies in knockout mice suggest that CTLA-4 controls effector T-cell function [40], CTLA-4 is constitutively expressed by Treg, which makes them a target of anti-CTLA-4 therapy [41].”
BackgroundHarnessing Immune Checkpoints for Cancer Therapy
Vinay, D. S., & Kwon, B. S. (2018) · Immunotherapy · doi:10.2217/imt-2017-0168 · Cited by 17
Busà, R., Bulati, M., Badami, E., Zito, G., Maresca, D. C., Conaldi, P. G., Ercolano, G., & Ianaro, A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.907572 · Cited by 16
“Similarly to the mouse model, it was observed an increase of CD4 T in patients that show cDC2 abundance to the detriment of Treg suggests that the combination of high levels of cDC2 and low levels of Treg correlate with better tumor prognosis and with clinical responsiveness to immunotherapy (including anti-PD-1 thera…”
ResultEnhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent
Diab, A. K., Jenq, R. R., Rizzuto, G. A., Cohen, A. D., Huggins, D., Merghoub, T., Engelhorn, M. E., Guevara-Patino, J. A., Suh, D. Y., Hubbard-Lucey, V. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082496 · Cited by 12
“Our results corroborate studies in both mouse models [36] and clinical studies [37], which indicate that the effector to regulatory T cell ratio can be a useful predictor for development of effective anti-tumor immune responses.”
Result
Metadata
- Authors
- Quezada, S. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Quezada, S. A.
- ORCID
- Quezada, S. A.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1935-1945
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1479425
- OpenAlex
- W2131874142
- Cited by
- 700
- References
- 50
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 22 · 2023: 37 · 2022: 31 · 2021: 44 · 2020: 35 · 2019: 37 · 2018: 41 · 2017: 46 · 2016: 29 · 2015: 41 · 2014: 41 · 2013: 39 · 2012: 38
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Cancer Research Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, GM-CSF, GVAX, tumor cell vaccine, regulatory T cells, effector T cells, B16-BL6 melanoma, antitumor immunity, Foxp3, CD8+ T cells, CD4+ T cells, tumor rejection, combination immunotherapy
- MeSH terms
- Animals, Antigens, Differentiation, Immunotherapy, Lymph Nodes, Melanoma, Experimental, Mice, Inbred C57BL, Antigens, CD, CD4 Antigens, T-Lymphocyte Subsets, Granulocyte-Macrophage Colony-Stimulating Factor, CD8 Antigens, Cancer Vaccines, Cell Line, Tumor, Cell Proliferation, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.